The combination of cabozantinib plus erlotinib for second or third-line treatments presents better efficacy, with manageable additional toxicity, than monotherapy with erlotinib for EGFR wild-type NSCLC patients[107]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.